Norah Lynn Henry MD PhD

Oncology•Ann Arbor, MI

Breast Cancer

Associate Professor

Join to View Full Profile

1500 E Medical Center DrAnn Arbor, MI 48109
Phone+1 734-936-6000

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2004 - 2007
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
Washington University in St. Louis School of MedicineClass of 2001
Stanford UniversityPhD, Structural Biology, 1991 - 1996

Certifications & Licensure

MI State Medical License 2004 - 2026
UT State Medical License 2016 - 2020
MA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure Start of enrollment: 2007 Aug 01
Terminated
Phase 2
A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy Start of enrollment: 2007 Sep 01
Completed
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain Start of enrollment: 2008 Oct 01
Completed
Not Applicable
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients Start of enrollment: 2009 Jul 01
Completed
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer Start of enrollment: 2009 Sep 01
Completed
Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain Start of enrollment: 2013 Oct 30
Completed
Phase 2
Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients Start of enrollment: 2013 Aug 01
Terminated
Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms Start of enrollment: 2013 Nov 01
Completed
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients Start of enrollment: 2013 Nov 01
Completed
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms Start of enrollment: 2009 Oct 01
Completed
Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients Start of enrollment: 2012 Mar 01
Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer Start of enrollment: 2014 May 30
Terminated
Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy Start of enrollment: 2006 Jun 01
Completed
Early Phase 1
Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer Start of enrollment: 2016 Mar 16
Terminated
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Characterizing Cannabidiol Use in a Breast Cancer Population.
Nicole M G Fleege, Bradley T Loeffler, Kevin F Boehnke, Norah Lynn Henry
Clinical Breast Cancer. 2025-02-07
Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04.
John Devin Peipert, Jessica Roydhouse, Mourad Tighiouart, Norah Lynn Henry, Sungjin Kim
Quality of Life Research. 2024-11-01
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Vinicius F Calsavara, Norah L Henry, Ron D Hays, Sungjin Kim, Michael Luu
Cancer Prevention Research. 2023-11-01

Lectures

Mindfulness and concerns about adjuvant endocrine therapy (AET).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

SABCS 2024: Clinical Impact of Advances in HR+ Breast CancerJanuary 2nd, 2025
Conference MDAngle: SABCS 2024 HR-Positive, HER2-Negative Breast CancerJanuary 2nd, 2025
Key Breast Cancer Advances at SABCS 2024December 2nd, 2024
Join now to see all

Grant Support

Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Breast CancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2027
Active Symptom Monitoring and Endocrine Therapy Persistence in Young Women with Breast CancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2027